Tuesday, July 27th, 2010
Top 3 Analyst Stock Picks and Recommendations
YES, I want free trades through Zecco.com!
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR), Covenant Transportation Group, Inc. (NASDAQ:CVTI) and Seattle Genetics, Inc. (NASDAQ:SGEN) are three analyst stock picks and recommendations made during today’s session.
Questcor Should Beat Earnings Estimates
Questcor Pharmaceuticals, Inc. (QCOR, Free Analysis), a pharmaceutical company focused on diseases and disorders, should beat tomorrow’s earnings expectations, according to Goldman Sachs. The analyst believes that the stock may benefit from the company’s potential announcement of an expansion of its salesforce, and maintains an Outperform rating on the stock.
During the second quarter, two analysts covering the pharmaceutical company expect it to earn $0.15 per share on revenues of $27.5 million, representing 8.8% year-over-year growth expectations. However, the firm fell a penny short of expectations during its first quarter, announcing earnings of $0.12 per share, versus $0.13 per share estimates.
Click Here: Get the Full QCOR Stock Analysis!
Covenant Transportation is Sharply Undervalued
Covenant Transportation Group, Inc. (CVTI, Free Analysis), a carrier for transportation companies and traditional truckload customers, could be worth as much as $15.00 per share, according to BB&T. The analyst upgraded the stock to a Buy, saying that it is benefiting from tightening truckload capacity and lean inventories that companies are maintaining, boosting expedited services.
U.S. freight companies have reported better-than-expected results during their latest earnings season as pricing continues to improve. Excess capacity had been putting pressure on prices, but a number of bankruptcies has reduced that capacity and helped margins. As a result, many firms expect continued strong demand throughout the second half of the year.
Click Here: Get the Full CVTI Stock Analysis!
Seattle Genetics Should See Positive Clinical Data
Seattle Genetics, Inc. (SGEN, Free Analysis), a clinical-stage biotechnology company focused on monoclonal anti-body based therapies, should see positive data from its Brentuximab Vedotin clinical trials, according to Oppenheimer. The analyst believes the stock is compelling ahead of the data and raised its price target to $15.00 per share with an Outperform rating.
Brentuximab vedotin is an antibody drug conjugate that’s target, CD30, is expressed on Hodgkin lymphoma, various T-cell cancers and other hematologic malignancies. Currently, the drug is undergoing clinical trials in patients with relapsed or refractory Hodgkin lymphoma under a Special Protocol Assessment with the FDA.
Click Here: Get the Full SGEN Stock Analysis!
Want to become a better trader? Click here to sign-up for a FREE trading e-course taught by a former floor trader!
-- Written by Simon Monger
